Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEKAMLO vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of aliskiren (direct renin inhibitor) and amlodipine (dihydropyridine calcium channel blocker). Aliskiren inhibits renin, reducing angiotensin I and II formation; amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Treatment of hypertension (FDA-approved) as replacement therapy in patients adequately controlled on individual components,Off-label: Not established
Hypertension
One tablet (40 mg telmisartan/5 mg amlodipine) orally once daily; maximum dose: 80 mg telmisartan/10 mg amlodipine per day.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Amlodipine terminal half-life: 30-50 hours (mean 35 hours), allowing once-daily dosing; steady-state achieved after 7-8 days. Valsartan terminal half-life: ~6 hours, but pharmacodynamic effect persists due to tight AT1 receptor binding.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Aliskiren: minimal metabolism via CYP3A4; amlodipine: extensively metabolized by CYP3A4
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
TEKAMLO (amlodipine/valsartan) excretion: amlodipine is extensively metabolized in the liver with 60% of metabolites excreted renally and 20-25% via feces; unchanged drug in urine <10%. Valsartan is primarily excreted unchanged in feces (70-80%) via biliary elimination, and 13% in urine as unchanged drug.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Amlodipine: ~97.5% bound to plasma proteins (albumin). Valsartan: 94-97% bound to serum proteins (mainly albumin).
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Amlodipine Vd: ~21 L/kg, indicating extensive extravascular distribution. Valsartan Vd: ~5-10 L/kg, indicating moderate distribution into tissues.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Amlodipine: oral bioavailability 64-90% (mean ~64%). Valsartan: oral bioavailability ~23% (range 10-35%). Both are administered orally only.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No adjustment for GFR ≥30 m L/min. Contraindicated if GFR <30 m L/min due to telmisartan component. Amlodipine not dialyzable.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Use lowest available strength, titrate slowly; avoid if severe impairment.
Child-Pugh Class B or C: contraindicated; use not recommended.
Safety and efficacy not established in patients <18 years.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at lowest available strength (40/5 mg); titrate slowly due to increased risk of hypotension and renal impairment.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
Risk of hypotension/syncope in volume-depleted patients,Avoid use in pregnancy (potential fetal harm),Monitor renal function and electrolytes, especially in patients with renal artery stenosis,Peripheral edema (more common in women, dose-dependent)
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Concomitant use with aliskiren in patients with diabetes or renal impairment (e GFR <60 m L/min) due to increased risk of renal impairment, hypotension, and hyperkalemia,Pregnancy,History of angioedema with aliskiren
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 metabolism of amlodipine, increasing risk of toxicity. Limit high-potassium foods (e.g., bananas, oranges, leafy greens, salt substitutes) due to aliskiren's potential to raise serum potassium. Maintain adequate hydration but avoid excessive sodium intake. No significant interaction with alcohol but advised to limit consumption.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Fetal toxicities (oligohydramnios, renal dysfunction, skull ossification delay) with angiotensin II receptor blocker (ARB) class. Second/third trimester: Oligohydramnios, fetal renal failure, hypotension, hyperkalemia, skull hypoplasia; risk is highest in second and third trimesters.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
No human data; amlodipine excreted in breast milk (M/P ratio ~1.0), telmisartan unknown. Avoid use while breastfeeding due to potential for neonatal hypotension and renal effects.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No dose adjustment recommended due to lack of pharmacokinetic studies in pregnancy; however, drug is contraindicated in pregnancy, especially second and third trimesters, and alternative antihypertensives should be used.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Tekamlo is a fixed-dose combination of aliskiren and amlodipine. Monitor renal function and electrolytes due to aliskiren's renin inhibition; avoid in severe renal impairment (e GFR <30 m L/min). Amlodipine may cause peripheral edema, especially at higher doses. Gradual titration reduces edema risk. Do not use aliskiren with ACE inhibitors or ARBs in patients with diabetes or renal impairment (e GFR <60 m L/min).
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take this medication exactly as prescribed, usually once daily.,Do not use with other blood pressure medications unless directed by your doctor.,Avoid grapefruit and grapefruit juice as they can increase amlodipine levels and side effects.,Report signs of edema (swelling in ankles/feet), dizziness, or fainting.,Do not take if you are pregnant or planning to become pregnant; stop immediately if pregnant.,Do not use salt substitutes containing potassium without consulting your doctor.,Stay hydrated, but avoid excessive intake of potassium-rich foods (bananas, oranges, spinach).,Do not stop abruptly without medical advice; monitor blood pressure regularly.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEKAMLO vs ALDORIL D30, answered by our medical review team.
TEKAMLO is a Antihypertensive combination that works by Combination of aliskiren (direct renin inhibitor) and amlodipine (dihydropyridine calcium channel blocker). Aliskiren inhibits renin, reducing angiotensin I and II formation; amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEKAMLO and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEKAMLO is: One tablet (40 mg telmisartan/5 mg amlodipine) orally once daily; maximum dose: 80 mg telmisartan/10 mg amlodipine per day.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEKAMLO and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEKAMLO is classified as Category C. First trimester: Fetal toxicities (oligohydramnios, renal dysfunction, skull ossification delay) with angiotensin II receptor blocker (ARB) class. Second/third trimester: Oligohydr. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.